Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 2090-2096

  Ardizzoni, Andrea ^a   Hansen, Heine ^a   Dombernowsky, Per ^a   Gamucci, Teresa ^a   Kaplan, Shoshana ^a   Postmus, Pieter ^a   Giaccone, Giuseppe ^a   Schaefer, Brigitte ^a   Wanders, Jantien ^a   Verweij, Jaap ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ETOPOSIDE; PLATINUM DERIVATIVE; TOPOTECAN;

ADULT; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0030913459     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.2090     Document Type: Article

References (24)

1. Hansen HH: Management of small-cell lung cancer. Lancet 339:846-849, 1992
2. Grant SC, Gralla RJ, Kriss MG, et al: Single agent chemotherapy trials in small cell lung cancer, 1970-1990: The case for studies in previously treated patients. J Clin Oncol 10:484-498, 1992
3. Giaccone G: Second line chemotherapy in small cell lung cancer. Lung Cancer 5:207-213, 1989
4. Figoli F, Veronesi A, Ardizzoni A, et al: Cisplatin and etoposide as second line chemotherapy in patients with small cell lung cancer. Cancer Invest 6:1-5, 1988
5. Albain KS, Crowley JJ, Hutchins L, et al: Predictors of survival following relapse or progression of small cell lung cancer. Cancer 72:1184-1191, 1993
6. Giaccone G, Donadio M, Bonardi G, et al: Teniposide in the treatment of small-cell lung cancer: The influence of prior chemotherapy. J Clin Oncol 6:1264-1270, 1988
7. Postmus PE, Smit EF, Kirkpatrick A, et al: Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: A phase II study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer Clin Oncol 29A:204-207, 1993
8. Postmus PE, Berendsen HH, Van Zandwijk N, et al: Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 23:1409-1411, 1987
9. Kingsbury WD, Boehm JC, Jakas DR, et al: Synthesis of water-soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 34:98-107, 1991
10. Rowinsky EK, Grochow LB, Hendricks CB, et al: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
11. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1990
12. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
13. Gehan E: The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chron Dis 13:346-353, 1961
14. Aisner J: Strategies for new drug identification in small cell lung cancer. Lung Cancer 9:S99-S107, 1993 (suppl 1)
15. Kauffman SH: Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51:1129-1136, 1991
16. Shiller JH, Kim K, Hutson P, et al: Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial. J Clin Oncol 14:2345-2352, 1996
17. Perez-Soler R, Glisson BS, Lee JS, et al: Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 14:2785-2790, 1996
18. Cullen MH, Smith SR, Benfield GFA, et al: Testing new agents may prejudice treatment: A phase II study of oral idarubicin in extensive disease small cell lung cancer. Cancer Treat Rep 71:1227-1230, 1987
19. Lund B, Hansen F, Hansen M, et al: Phase II study of 1, 2, 4 triglycidylaruzol (TGU) in previously untreated and treated patients with small cell lung cancer. Eur J Cancer Clin Oncol 23:1031-1033, 1987
20. Ardizzoni A, Pennucci C, Fusco V, et al: Oral chemotherapy for poor risk small-cell lung cancer patients with combined idarubicin and etoposide. Anticancer Res 9:937-940, 1989
21. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
22. Ettinger DS, Finkelstein DM, Sarma R, et al: Phase II study of Taxol in patients (pts) with extensive-stage small cell lung cancer (SCLC): An Eastern Cooperative Oncology Group study. Proc Am Soc Clin Oncol 12:329, 1993 (abstr 1094)
23. Kirshling RJ, Jung SH, Jett JR: A phase II trial of Taxol and G-CSF in previously untreated patients with extensive-stage small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 13:326, 1994 (abstr)
24. Cormier Y, Eisenhauer EA, Muldal A, et al: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). Ann Oncol 5:283-285, 1994